clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Parola D et al. [Efficacy and safety of clarithromycin in the treatment of community-acquired pneumonia]. 2000 Recenti Prog Med pmid:10705778
Fonquernie L et al. [Pseudotumoral abdominal granuloma concomitant with immune reconstitution after antiretroviral treatment]. 2000 Presse Med pmid:10705894
Luman W et al. One week triple therapy for Helicobacter pylori associated duodenal ulcer disease. 1999 Singapore Med J pmid:10709423
Coelho LG et al. Once-daily Helicobacter pylori treatment to family members of gastric cancer patients. 2000 Am. J. Gastroenterol. pmid:10710099
Pilotto A et al. In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. 2000 Am. J. Gastroenterol. pmid:10710100
Kearney DJ and Brousal A Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients. 2000 Dig. Dis. Sci. pmid:10711436
Lõivukene K et al. Metronidazole and clarithromycin susceptibility and the subtypes of vacA of Helicobacter pylori isolates in Estonia. 2000 Scand. J. Infect. Dis. pmid:10716079
Edlund C et al. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. 2000 Scand. J. Infect. Dis. pmid:10716083
Ani AE et al. Antimicrobial susceptibility test of Helicobacter pylori isolated from Jos, Nigeria. 1999 Nov-Dec Trans. R. Soc. Trop. Med. Hyg. pmid:10717760
Tran JQ et al. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. 2000 J. Antimicrob. Chemother. pmid:10719007
Brophy DF et al. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. 2000 Antimicrob. Agents Chemother. pmid:10722500
Numazaki K et al. Therapeutic effect of clarithromycin for respiratory-tract infections in children caused by Chlamydia pneumoniae. Research Group of Sapporo for Pediatric Chlamydial Infections. 2000 Int. J. Antimicrob. Agents pmid:10724028
Gomollón F et al. [Does eliminating Helicobacter pylori mean the healing of the duodenal ulcer? The results of a prospective study in Spain]. 2000 Gastroenterol Hepatol pmid:10726384
Telenti A and Iseman M Drug-resistant tuberculosis: what do we do now? 2000 Drugs pmid:10730543
Lehmann FS et al. Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. 2000 Aliment. Pharmacol. Ther. pmid:10735923
Miwa H et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. 2000 Aliment. Pharmacol. Ther. pmid:10735925
Spinzi GC et al. Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study. 2000 Aliment. Pharmacol. Ther. pmid:10735926
Blackington E The gastric demon. An update on Helicobacter pylori infection. 1999 Adv Nurse Pract pmid:10745720
Paton R et al. Susceptibility testing of Haemophilus influenzae to clarithromycin. 2000 J. Antimicrob. Chemother. pmid:10747833
Shashidhar H et al. A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection. 2000 J. Pediatr. Gastroenterol. Nutr. pmid:10749411
Joosen EA et al. Costs and benefits of a test-and-treat strategy in Helicobacter pylori-infected subjects: a prospective intervention study in general practice. 2000 Eur J Gastroenterol Hepatol pmid:10750653
Woo PC et al. Clarithromycin attenuates cyclophosphamide-induced mucositis in mice. 2000 Pharmacol. Res. pmid:10753551
Bassetti M et al. Erythromycin resistance in Streptococcus pyogenes in Italy. 2000 Mar-Apr Emerging Infect. Dis. pmid:10756153
Shibuya N et al. [Effect of clarithromycin on adhesion and infiltration of cancer cells]. 2000 Jpn J Antibiot pmid:10756451
Majima T et al. [Administration of clarithromycin (CAM) to non-small cell lung cancer]. 2000 Jpn J Antibiot pmid:10756452
Matsunaga Y et al. [Effect of clarithromycin on KL-8 formation by epidermal keratocytes]. 2000 Jpn J Antibiot pmid:10756455
Miyanohara T et al. [Effects of macrolides on cultured cells derived from the nose]. 2000 Jpn J Antibiot pmid:10756463
Sato Y et al. [Effect of long-term administration of small dosages of clarithromycin for the treatment of uterine pyometra]. 2000 Jpn J Antibiot pmid:10756466
Fukushima K et al. [Outstanding efficacy of a macrolide in a small dosage for the treatment of refractory skin fistula communicating with the thoracic cavity and accompanying pyothorax]. 2000 Jpn J Antibiot pmid:10756469
Douthwaite S et al. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. 2000 Mol. Microbiol. pmid:10760175
Matsiota-Bernard P et al. Comparison of clarithromycin-sensitive and clarithromycin-resistant Mycobacterium avium strains isolated from AIDS patients during therapy regimens including clarithromycin. 2000 J. Infect. pmid:10762111
Benson CA et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. 2000 J. Infect. Dis. pmid:10762562
MacArthur RD et al. Effects of Mycobacterium avium complex-infection treatment on cytokine expression in human immunodeficiency virus-infected persons: results of AIDS clinical trials group protocol 853. 2000 J. Infect. Dis. pmid:10762582
Trebesius K et al. Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation. 2000 Gut pmid:10764702
Schenk BE et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. 2000 Gut pmid:10764703
Kadir T et al. In vitro effects of clarithromycin on human polymorphonuclear leukocyte functions. 2000 May-Jun Chemotherapy pmid:10765036
Gasbarrini A et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. 2000 Scand. J. Gastroenterol. pmid:10766318
Offman E et al. Oral absorption of clarithromycin in acute illness and during convalescence in patients with community-acquired pneumonia. 2000 Chest pmid:10767245
Bojarski C et al. Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out. 2000 Z Gastroenterol pmid:10768243
Adamsson I et al. Microbial ecology and treatment of Helicobacter pylori infections: review. 2000 J Chemother pmid:10768510
Singer J et al. Symptomatic and health status outcomes in the Canadian randomized MAC treatment trial (CTN010). Canadian HIV Trials Network Protocol 010 Study Group. 2000 Int J STD AIDS pmid:10772083
Najib MM et al. Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia. 2000 Pharmacotherapy pmid:10772376
Fujimura S et al. Clarithromycin-susceptible Helicobacter pylori with mutation in 23S rRNA gene by PCR-RFLP method. 2000 J. Gastroenterol. pmid:10777165
Abisheganaden JA et al. Effect of clarithromycin on experimental rhinovirus-16 colds: a randomized, double-blind, controlled trial. 2000 Am. J. Med. pmid:10781777
Kane CL et al. Disseminated cutaneous Mycobacterium chelonae infection. 2000 Mar-Apr Cancer Control pmid:10783823
Shibl AM et al. Penicillin-resistant and -intermediate Streptococcus pneumoniae in Saudi Arabia. 2000 J Chemother pmid:10789552
Waites K et al. Use of clindamycin disks To detect macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae isolates from adults and children. 2000 J. Clin. Microbiol. pmid:10790089
Marini RP et al. Ranitidine bismuth citrate and clarithromycin, alone or in combination, for eradication of Helicobacter mustelae infection in ferrets. 1999 Am. J. Vet. Res. pmid:10791942
Calvet X et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. 2000 Aliment. Pharmacol. Ther. pmid:10792124
Shimizu T et al. Successful treatment using clarithromycin for a cutaneous lesion caused by Mycobacterium szulgai. 2000 Br. J. Dermatol. pmid:10792258
Vernet Vernet M et al. [Analysis of indications and diagnosis of the gastroscopies requested by primary care physicians]. 2000 Aten Primaria pmid:10795440
Boyanova L et al. Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria. 2000 J. Med. Microbiol. pmid:10798553
Boruchoff SE et al. The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin. 2000 Clin. Pharmacol. Ther. pmid:10801243
Azuma T et al. Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. 2000 Aliment. Pharmacol. Ther. pmid:10807427
Suzuki H et al. Prognostic factors of chronic rhinosinusitis under long-term low-dose macrolide therapy. 2000 May-Jun ORL J. Otorhinolaryngol. Relat. Spec. pmid:10810255
Rhee CS et al. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. 2000 Ann. Otol. Rhinol. Laryngol. pmid:10823478
Zuckerman JM The newer macrolides: azithromycin and clarithromycin. 2000 Infect. Dis. Clin. North Am. pmid:10829265
Flockhart DA et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. 2000 J Clin Psychopharmacol pmid:10831018
Spiegel JR et al. Prolonged ulcerative laryngitis. 2000 Ear Nose Throat J pmid:10832196
Miyashita N et al. In vitro susceptibility of 7.5-kb common plasmid-free Chlamydia trachomatis strains. 2000 Microbiol. Immunol. pmid:10832970
Gisbert JP et al. One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. 2000 Eur J Gastroenterol Hepatol pmid:10833090
Kaushik SP and Vu C Helicobacter pylori eradication with lansoprazole, amoxycillin and clarithromycin: testing an ideal regimen in a multicultural south east Asian population and examining factors potentially influencing eradication. 2000 Aust N Z J Med pmid:10833116
Laine L et al. Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori. 2000 Gastrointest. Endosc. pmid:10840297
Romero Gómez M et al. [Usefulness of Helicobacter pylori antigen detection in stools in the diagnosis of infection and confirming eradication after treatment]. 2000 Med Clin (Barc) pmid:10846675
Baños F et al. [Effectiveness of omeprazole, clarithromycin and amoxycillin therapy to eradicate Helicobacter pylori in patients with active peptic ulcer. Preliminary results of GENPY study]. 2000 Med Clin (Barc) pmid:10846695
Zullo A et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. 2000 Aliment. Pharmacol. Ther. pmid:10848654
Moayyedi P et al. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. 2000 Aliment. Pharmacol. Ther. pmid:10848655
Katelaris PH et al. Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. 2000 Aliment. Pharmacol. Ther. pmid:10848659
Ammon S et al. Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. 2000 Aliment. Pharmacol. Ther. pmid:10848660
Leiper K et al. Open label trial of oral clarithromycin in active Crohn's disease. 2000 Aliment. Pharmacol. Ther. pmid:10848665
Bhasin DK et al. Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of Helicobacter pylori: a report from India. 2000 Helicobacter pmid:10849056
Nagahara A et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. 2000 Helicobacter pmid:10849057
Hammerschlag MR and Roblin PM Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. 2000 Int. J. Antimicrob. Agents pmid:10854812
Hirschl AM et al. In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori. 2000 Antimicrob. Agents Chemother. pmid:10858365
Miltner EC and Bermudez LE Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. 2000 Antimicrob. Agents Chemother. pmid:10858369
Drago L et al. Comparative effect of thiamphenicol glycinate, thiamphenicol glycinate N-acetylcysteinate, amoxicillin plus clavulanic acid, ceftriaxone and clarithromycin on pulmonary clearance of Haemophilus influenzae in an animal model. 2000 Jul-Aug Chemotherapy pmid:10859433
Mikasa K [Study of effects and mechanisms of macrolide as biological response modifier for lung cancer treatment]. 2000 Jpn J Antibiot pmid:10868303
Fraser AG et al. Helicobacter pylori treatment and antibiotic susceptibility: results of a five-year audit. 1999 Aust N Z J Med pmid:10868529
Amayasu H et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. 2000 Ann. Allergy Asthma Immunol. pmid:10875487
Maggiolo F et al. In-vitro activity of moxifloxacin combined with other antibacterials against methicillin-resistant Staphylococcus aureus. 2000 J Chemother pmid:10877512
Suzuki K et al. [Fibrosing alveolitis following Legionella pneumonia]. 2000 Nihon Kokyuki Gakkai Zasshi pmid:10879037
Erel F et al. Impact of Helicobacter pylori and Giardia lamblia infections on chronic urticaria. 2000 Mar-Apr J Investig Allergol Clin Immunol pmid:10879997
Delchier JC [How to eradicate Helicobacter pylori?]. 1999 Gastroenterol. Clin. Biol. pmid:10880913
Yanagihara K et al. Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation. 2000 J. Antimicrob. Chemother. pmid:10882691
Saito K et al. Effect of Helicobacter pylori eradication on malignant transformation of gastric adenoma. 2000 Gastrointest. Endosc. pmid:10882958
Savarino V et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. 2000 Aliment. Pharmacol. Ther. pmid:10886045
Wang WH et al. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. 2000 Aliment. Pharmacol. Ther. pmid:10886046
Sung JJ et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. 2000 Gastroenterology pmid:10889149
Lamouliatte H et al. [Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers]. 2000 Gastroenterol. Clin. Biol. pmid:10891736
Toutous-Trellu L et al. Three cases of cutaneous sarcoidosis: search for bacterial agent by the 16S RNA gene analysis and treatment with antibiotics. 2000 Dermatology (Basel) pmid:10894973
Konno M et al. Iron-deficiency anemia associated with Helicobacter pylori gastritis. 2000 J. Pediatr. Gastroenterol. Nutr. pmid:10896071
Jamal MA et al. Molecular basis of clarithromycin-resistance in Mycobacterium avium intracellulare complex. 2000 Tuber. Lung Dis. pmid:10897378
Jordan MK et al. Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics. 2000 Antimicrob. Agents Chemother. pmid:10898693
Kato M et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. 2000 Antimicrob. Agents Chemother. pmid:10898707
Bortolotti M et al. Dose-related stimulatory effect of clarithromycin on interdigestive gastroduodenal motility. 2000 Digestion pmid:10899723
Moayyedi P et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group. 2000 Lancet pmid:10905240
Miwi H et al. Comparison of the efficacy of 400mg and 800mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population. 2000 J. Gastroenterol. pmid:10905362
McCarty J et al. Clarithromycin suspension vs penicillin V suspension in children with streptococcal pharyngitis. 2000 Jan-Feb Adv Ther pmid:10915400
Lerner FE et al. Clarithromycin bioequivalence study of two oral formulations in healthy human volunteers. 2000 Int J Clin Pharmacol Ther pmid:10919343
Frueh BE et al. Mycobacterium szulgai keratitis. 2000 Arch. Ophthalmol. pmid:10922211